NCT02779764 - A Long Term Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia Converted From Erythropoieses Stimulating Agent (ESA) Treatment | Biotech Hunter

Enrollment

164

Participants

Timeline

Start Date

May 16, 2016

Primary Completion Date

May 16, 2017

Study Completion Date

November 28, 2017

Conditions

Hemodialysis Patients With Renal Anemia

Interventions

DRUG

roxadustat

Oral

Trial Locations (25)

Site JP00017, Aichi

Site JP00005, Fukuoka

Site JP00004, Gunma

Site JP00006, Gunma

Site JP00018, Hokkaido

Site JP00019, Hokkaido

Site JP00021, Hokkaido

Site JP00023, Hyōgo

Site JP00008, Ibaraki

Site JP00020, Ishikawa

Site JP00010, Kumamoto

Site JP00022, Kumamoto

Site JP00024, Kumamoto

Site JP00016, Kyoto

Site JP00002, Nagano

Site JP00012, Nagano

Site JP00015, Nagano

Site JP00003, Niigata

Site JP00025, Osaka

Site JP00007, Saitama

Site JP00009, Shizuoka

Site JP00014, Tokyo

Site JP00013, Tottori

Site JP00011, Wakayama

Site JP00001, Yamaguchi